Mounjaro®
Starting from £179.99/mo
Start journey Learn moreOn 1st September 2025, Eli Lilly raised Mounjaro's UK list price substantially. The highest-dose pen moved from around £122 to around £330 per four-week supply, with private providers typically charging somewhere in the range of £149 to £375 per month depending on dose and clinic. These are prescription-only medicines: a prescriber must assess your suitability before any treatment can be dispensed. The price rise is real, it affects every legitimate UK provider, and understanding what sits behind any headline figure is worth doing before you commit. Our detailed breakdown of what drove the September price increase covers the background in full, but this page focuses on what the change means in practical terms.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Eli Lilly's revised UK list price took effect on 1st September 2025. Before that date, a single Mounjaro KwikPen at the highest maintenance strength (15mg) carried a list price of around £122. From that date the same pen's list price rose to around £330, a figure that has been widely reported and confirmed by Lilly UK. Lower doses sit at lower price points, so the monthly cost varies considerably depending on which strength your prescriber has you on.
Private providers set their own retail prices on top of the manufacturer's list price, which is why the market range of roughly £149 to £375 per month exists. That spread reflects dose, provider overheads, and what is or isn't included in the quote. If you want to see exactly how that range breaks down by strength, our detailed look at Mounjaro prices this September covers the full picture and shows what each dose tier is likely to cost you.
One thing hasn't changed: Mounjaro remains a Prescription-Only Medicine. The September list-price revision applied to the medicine itself, it had no bearing on the legal requirement for a clinical assessment before any pen can be dispensed. A prescriber still decides suitability; a pharmacy you can verify on the GPhC register still has to dispense it. If you'd like a straightforward summary of what Mounjaro prices look like from September, that page sets out the current figures by dose. The route to treatment is the same; the cost is higher.
A monthly figure quoted in a search result or comparison site may not include everything you'll actually pay. Consultation fees are sometimes charged separately. Prescription fees (a real cost in private medicine) may be added at checkout. Delivery charges, which can run to £10 or more per order, are sometimes listed as a footnote. Aftercare or dose-review support, which matters considerably over a year-long treatment course, may be a paid add-on or simply absent.
This is worth knowing because the September price rise made those extras more visible. When the base cost was lower, a £10 delivery charge or a £25 consultation fee was a smaller proportion of the total. Now that the medicine itself costs more, a provider's decision about what to bundle or unbundle has a larger effect on your real monthly spend. Our guide to what Mounjaro actually costs from September walks through each of those line items.
It is also worth checking whether the provider you're looking at is on the GPhC register. The MHRA has warned publicly about counterfeit weight-loss pens sold online, and the Yellow Card scheme allows anyone to report a suspect seller. A price that looks dramatically below the market range is a meaningful red flag, not a bargain.
We are not the cheapest option available. That is a deliberate position, not an oversight. One transparent price covers the clinical consultation, the prescription, the medicine, and next-working-day tracked delivery by DPD, dispatched the same day if you order before 12pm and your prescriber approves your treatment. The pen arrives in plain, unbranded packaging; you can follow your delivery on DPD's tracking link the way you would any other parcel. There are no subscriptions and no auto-renewals. Every repeat order goes through a fresh clinical review, the same prescriber model, not an algorithm making a decision on your behalf.
Our current treatment pricing is shown clearly on the weight-loss treatments page. We don't print per-pen prices in body copy because they move with the supply chain, and a figure in an article can go stale faster than the page does. The treatments page is always current.
If you want to understand more about how Mounjaro works and what the clinical evidence shows, the Mounjaro overview is a good starting point, and our weight-loss treatment guide explains how the different options compare.
Price is a fair thing to think about, treatment at these costs is a meaningful household expense, and the September rise made that more true. But for a prescription medicine, the lowest number on a comparison page is the wrong thing to optimise for. The question that keeps you safer is: is this a pharmacy I can verify, dispensing genuine medicine from the licensed UK supply chain, with a real prescriber making the clinical decision?
The MHRA's guidance on weight-loss medicines is clear that GLP-1 medicines are not assessed for quick or cosmetic use, and must go through proper clinical channels. Providers who appear to offer Mounjaro at prices well below the post-September market range, with minimal or no clinical process, are worth approaching with considerable caution.
A small saving per month isn't the measure that tells you whether treatment is safe, genuine, or clinically right for you. A prescriber who has reviewed your health history, verified your identity, and taken responsibility for the prescription, that is the measure. If you'd like to understand the full picture of how September's changes affect ongoing treatment costs, our page on the September price increase in context is worth reading alongside this one. When you're ready to take the next step, start your free consultation and a GPhC-registered prescriber will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.